SUDA Pharmaceuticals Ltd (ASX:SUD) (FRA:E4N) has appointed leading US-based cancer researcher Dr Anil K Sood to its Scientific Advisory Board.
Dr Sood is professor and vice-chair for translational research in the departments of Gynecologic Oncology and Cancer Biology and co-director of the Center for RNA Interference and Non-Coding RNA at The University of Texas MD Anderson Cancer Center.
He is also director of the multi-disciplinary Blanton-Davis Ovarian Cancer Research Program and co-leads the Ovarian Cancer Moon Shot Program.
Add enormously to SUDA’s program
SUDA chief executive officer and managing director Dr Michael Baker said: “We are thrilled that Dr Sood is joining our scientific advisory board.
"He has pioneered the research underpinning the role that platelets play in the progression of cancer.
“We believe that Dr Sood will add enormously to the program, given his deep understanding of platelet biology in the clinical setting.”
Dr Sood
Dr Sood received his medical degree from the University of North Carolina, Chapel Hill, North Carolina.
He has received major recognition for his research accomplishments, including the Hunter Award, the Margaret Greenfield/Carmel Cohen Excellence in Ovarian Cancer Research Prize, and the GCF/Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher.
He is an elected member of the American Society for Clinical Investigation (ASCI), the American Association for the Advancement of Science (AAAS), and the Association of American Physicians (AAP).
Dr Sood was appointed as an American Cancer Society Professor in 2017.
He was the lead investigator in a seminal publication that was published in the New England Journal of Medicine, describing the role that platelets play in ovarian cancer in relation to reducing patient survival.
Anagrelide update
SUDA continues to progress with the development of its oral spray formulation of anagrelide to be used as an adjunct therapy for patients with thrombocytosis (elevated platelets) and metastatic disease.